ArticleHuman vaccines & immunotherapeutics2026
Advancing the understanding of the immune escape in lung cancer immunotherapy: Global trends, collaborations, and future directions.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune escape mechanisms critically restrict the efficacy of immunotherapy in lung cancer (LC), with only 20%-30% of patients responding to checkpoint inhibitors. To systematically map global trends and identify emerging hotspots, this study analyzed 2813 publications related to immune escape in LC immunotherapy from 1995 to 2025 (data retrieved August 9, 2025; analysis of annual trends uses complete year data through 2024) sourced from the Web of Science Core Collection database. Bibliometric visualization was performed using VOSviewer (version 1.6.19), CiteSpace (version 6.2.R3), and the biblioshiny R package. The dataset encompassed 75 countries, 3421 institutions, and 18,023 researchers across 693 journals. Publication trends delineated three distinct phases: an initial phase (1995-2010), an acceleration phase (2011-2018), and a maturation phase (2019-2024). China dominates in publication volume (1,382 papers) and total citations (45,657), whereas the University of Texas MD Anderson Cancer Center emerged as the most influential institution (n = 87). The
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.